# Post-Edit Outline - REN-01 Manuscript (2026-01-20)

## Document Structure (78 pages)

### Front Matter (Pages 1-2)

**Title Page (Page 1)**
- Title: REN-01: A Novel Opioid-Derived Compound for Stabilizing Recursive Entropy Dynamics in Dopaminergic Neural Circuits
- Author: Christopher Ezernack
- Date: January 20, 2026
- Copyright: 2025 REOP Solutions

**Abstract**
- Definitions introduced: REN-01, EntPTC2, entropy proxy φ_E, dopamine proxy ψ_D, astrocyte proxy A, collapse metric χ
- Key constraint: Quaternion components are algebraic only, not physical coordinates/rotations/trajectories
- Key constraint: Entropy proxy is not thermodynamic entropy; stabilization limits accumulation, does not reverse
- Results (SIMULATED): healthy χ=5.17±0.83, degenerative χ=0.92±0.31, REN-01 χ=6.90±1.05
- Limitations: All results are model outputs requiring experimental validation

**Disclaimer (Page 2)**
- Explicit statement: theoretical and computational framework only
- No clinical claims made
- All therapeutic potential requires rigorous experimental validation

### Section 1: Introduction (Pages 2-4)
- Background on Parkinson's disease pathology
- Limitations of current therapeutic approaches
- Introduction of entropy field hypothesis
- Assumptions: dopaminergic circuits operate in metastable regime

### Section 2: REN Platform Overview (Pages 4-5)
- REN-01: Parkinson's Disease (instantiated model)
- REN-02: Alzheimer's Disease (conceptual framework)
- REN-03: Schizophrenia (conceptual framework)
- REN-04: ALS (conceptual framework)
- REN-05: Epilepsy (conceptual framework)

### Section 3: Quaternionic Framework (Pages 5-8)
- Definitions: Q(x,t) quaternion field, quaternionic Hilbert space H^n
- Key constraint: Algebraic formalism only, not quantum mechanics claim
- Key constraint: No spatial rotations, trajectories, or geometric embeddings
- Equations: Quaternion multiplication, norm preservation
- Assumptions: Deterministic phase space structure

### Section 4: Chemical Structure (Pages 8-12)
- TRV130/oliceridine core structure
- MOR agonist properties (K_i ~5 nM, α_D=0.667)
- CB2 selective ligand component
- PEG5 linker specifications
- REN-01 molecular structure placeholder (Figure 2)

### Section 5: Blood-Brain Barrier Delivery (Pages 12-18)
- MIF stealth complex mechanism
- Astrocyte targeting domain
- CSF barrier protocol
- System schematic (Figure 1)

### Section 6: Mathematical Model (Pages 18-35)
**6.1 Model Scope and Assumptions**
- Primary state variable: Q(x,t) is sole dynamical variable
- Scalar fields (φ_E, ψ_D, A) are derived diagnostics
- |Ψ⟩ notation is motivational bridge only

**6.2 Governing Equations**
- Quaternion evolution equation
- Noise term η(x,t) with correlation structure
- Coupling coefficients (α, β, γ)

**6.3 Parameter Values**
- All parameters literature-motivated (not fitted)
- D_Q = 0.1 mm²/s (diffusion)
- τ = 100 ms (time constant)
- σ = 0.3 (noise amplitude)

**6.4 Scalar Projections**
- φ_E = q_1² + q_2² + q_3² (entropy proxy)
- ψ_D = q_0² (dopamine proxy)
- A = q_2² (astrocyte proxy)

**6.5 Collapse Metric χ**
- CANONICAL DEFINITION: χ = ψ_D / (1 + φ_E)
- This is the single authoritative definition
- All reported χ values use this formula

### Section 7: Simulation Results (Pages 35-48)
- Three regime comparison (healthy, degenerative, REN-01)
- Results (ALL SIMULATED):
  - Healthy: χ = 5.17 ± 0.83, ψ_D = 0.87
  - Degenerative: χ = 0.92 ± 0.31, ψ_D = 0.14
  - REN-01: χ = 6.90 ± 1.05, ψ_D = 0.91
- Ablation studies: MOR 75%, CB2 18%, entropy 7%
- Regime uniqueness tests: p < 10^-80

### Section 8: Validation Framework (Pages 48-55)
- Internal model validation only (not experimental proof)
- Consistency checks
- Sensitivity analysis
- Limitations acknowledged

### Section 9: Experimental Plan (Pages 55-60)
- Proposed synthesis pathway
- Proposed in vitro assays
- Proposed animal model studies
- All future work requiring funding and collaboration

### Section 10: Discussion (Pages 60-64)
- Interpretation of simulation results
- Comparison to existing approaches
- Limitations of theoretical framework
- Future directions

### Section 11: Conclusion (Pages 64-65)
- Summary of theoretical contributions
- REN-01 as test perturbation of regime dynamics
- Important disclaimer paragraph reinforcing simulation-only status

### Unnumbered Appendix: REN-02-05 Placeholders (Pages 65-68)
- Figure 14: REN-02 placeholder (Alzheimer's)
- Figure 15: REN-03 placeholder (Schizophrenia)
- Figure 16: REN-04 placeholder (ALS)
- Figure 17: REN-05 placeholder (Epilepsy)
- All marked as conceptual frameworks only

### Appendix A: Future Work and Extensions (Pages 68-76)
**A.1 Extension to Other Neurodegenerative Disorders**
- A.1.1 Alzheimer's Disease
- A.1.2 Schizophrenia
- A.1.3 Non-neuronal Cell Systems

**A.2 Refinement of the Theoretical Framework**
- A.2.1 Advanced Mathematical Modeling
- A.2.2 Computational Implementations

**A.3 REN-02 through REN-05 (Conceptual Frameworks Only)**
- Explicit note: not instantiated as specific molecular designs
- Not validated drug candidates

### References (Pages 76-78)
- 44 citations
- OpenNeuro ds000245 cited
- PubChem CID 66553195 cited

## Key Constraints Enforced Throughout

1. **Q(x,t) as sole primary state**: All scalar fields derived from Q
2. **Algebraic-only quaternions**: No geometry, rotations, trajectories
3. **Single χ definition**: Canonical formula used consistently
4. **Literature-motivated parameters**: Not fitted to data
5. **Internal validation only**: Not experimental proof
6. **Simulation framing**: All results are model outputs
7. **REN-01 only instantiated**: REN-02-05 are conceptual frameworks
